Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03381950 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 22, 2017
Last Update Posted : October 11, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Preserving kidney function and improving the transition from CKD to End stage renal disease (ESRD) is a research and healthcare challenge. The Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort was established to identify the determinants, biomarkers and practice patterns associated with chronic kidney disease outcomes. The study includes 3,033 adult patients with moderate to advanced CKD from a representative sample of 40 nephrology clinics in France with respect to regions and legal status. Patients are recruited during a routine visit and followed up for 5 years, before and after starting renal replacement therapy. Patient-level clinical, biological, and lifestyle data are collected annually, as well as provider-level data on clinical practices, coordinated with the International Chronic Kidney Disease Outcomes and Practice Pattern Study (CKDopps). Blood and urine samples are stored in a biobank. The overall objective is to develop a research platform to address key questions regarding the determinants and biomarkers associated with adverse outcomes in CKD and to assess its effective management. It has the following hypotheses and specific aims:
- to evaluate a large set of social, environmental, bioclinical, and genetic factors, and their interactions in relation with CKD outcomes including progression to ESRD, mortality, metabolic and vascular complications, and the onset of a number of chronic and acute events;
- to assess several new biomarkers to predict adverse outcomes of CKD and its complications;
- to evaluate the associations of provider practices (management of hypertension, anemia, nutritional abnormalities, mineral and bone disorder, nutritional status, timing of dialysis initiation and transplant wait-listing) with achievement of clinical practice guidelines, clinical and patient-reported outcomes (PRO).
- to evaluate the associations of health care organization and clinic services (e.g., for nutrition, educational programs) with clinical and patient-reported outcomes, and achievement of clinical practice guidelines;
- to estimate the relative cost-effectiveness of different provider practices and clinic services.
| Condition or disease |
|---|
| Renal Insufficiency, Chronic |
All cohort participants are assessed annually for at least 5 years, until 6 months after the start of renal replacement therapy.
Each year, data are collected from both medical records and patients interview and self-administrated questionnaires are asked to report clinical events.
Interviews and routine biological measurements are repeated annually.
CKD-REIN is funded by the Agence Nationale de la Recherche through the 2010 'Cohortes-Investissements d'Avenir' programme and by the 2010 national Programme Hospitalier de Recherche Clinique.
CKD-REIN is also supported through a public-private partnership with Amgen, Fresenius Medical Care, and GlaxoSmithKline since 2012; Baxter and MerckSharp&Dohme-Chibret (France) from 2012 to 2017; LillyFrance since 2013; Otsuka Pharmaceutical since 2015; Vifor Fresenius since 2017; AstraZeneca since 2018; and Sanofi-Genzyme from 2012 to 2015.
| Study Type : | Observational |
| Actual Enrollment : | 3033 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Chronic Kidney Disease - Renal Epidemiology and Information Network: The CKD-REIN Cohort |
| Actual Study Start Date : | July 2013 |
| Estimated Primary Completion Date : | July 2021 |
| Estimated Study Completion Date : | December 2026 |
- Incidence of end-stage renal disease (ESRD) [ Time Frame: up to 5 years ]Dialysis, transplantation, conservative care management
- Mortality [ Time Frame: up to 5 years ]Specific and all-cause mortality
- Incidence of major CKD events including acute kidney injury, cardiovascular and metabolic complications [ Time Frame: up to 5 years ]
- Incidence of major adverse events including infections, cancer, mineral and bone disease, anemia, nutitional status, hospitalizations [ Time Frame: up to 5 years ]
- Prescription drug use [ Time Frame: up to 5 years ]For each drug prescription, the trade name, international non-proprietary name, ATC class, unit dose, defined daily dose, pharmaceutical formulation, and administration route are recorded. A linkage with the drug reimbursement files from the health insurance will be also performed.
- Health-related Quality of life [ Time Frame: up to 5 years ]Assessed by the Kidney Disease Quality of Life (KDQOL™) scale. It is a measure of kidney disease-related quality of life that comprises four subscales: Generic core [Physical Component Summary (PCS) and Mental Component Summary (MCS)]; Symptoms/Problems; Burden of Kidney Disease, and Effects of Kidney Disease. Scores of each subscale are calculated, ranged from 0 to 100, with higher scores reflecting better quality of life.
- Depression [ Time Frame: up to 5 years ]Assessed by the 10-item Center for Epidemiologic Studies Depression Scale (CESD). It is a screening test for depression and depressive disorder. A total score is reported.The possible range is 0 to 30, with the higher scores indicating more depression symptoms.
- Cognitive function [ Time Frame: up to 5 years ]The 30-item minimental status examination (MMSE) is a practical tool for evaluating cognitive status. A total score is reported, ranged from 0 to 30, with the higher scores indicating less cognitive impairment.
- Physical Activity [ Time Frame: up to 5 years ]The French translation of the Global Physical Activity Questionnaire (Version 2.0) is used to gather information on the time spent in moderate and vigorous physical activity and in sedentary behavior. The GPAQ contains 16 items designed to assess the frequency and duration of physical activity in 3 domains: during work, transportation, and leisure time as well as time spent sitting during a typical week. It distinguishes physical activity duration by min/day and min/week for each physical activity domain, which allows for calculating the energy expenditure scored in metabolic equivalent tasks (METs). According to duration and energy expenditure, physical activity level was classified as low, moderate, and high.
- Family relationships [ Time Frame: up to 5 years ]Assessed by the Family Relationships Index (FRI). the FRI provides a brief measure of family relations by assessing the way people currently perceive and describe their family. The scale consists of 12 items. Each item is coded from 1 to 4. A validation study of this questionnaire is planned.
- Sleep disorders [ Time Frame: up to 5 years ]
- Women's health [ Time Frame: up to 5 years ]Set of questions regarding the menopause, menstrual cycle and contraception, and past/in progress pregnancies.
- Cost effectiveness of different treatment practices and services [ Time Frame: up to 5 years ]
Several data sources will be used to estimate the cost of different treatment practices and services.
Patient-Level: key resource utilization indicators (e.g., hospitalization, clinic visits, prescription drug use), and procedures for costing these measures.
Clinic-level: The net costs of different treatment practices as well as structural characteristics (such as number of beds of the hospital, number of wards, number of hierarchical levels, for-profit or non for-profit status, teaching or not teaching hospital, spatial organization).
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- eGFR < 60 ml/min/1.73m2 for at least 1 month
- no prior chronic dialysis or transplantation
- Written Signed consent form
Exclusion Criteria:
- Age <18 yrs old,
- Pregnant female,
- patients who plan to move
- Unable to give inform consent,
- Decline to participate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03381950
| Principal Investigator: | Bénédicte Stengel, MD | Inserm U1018, UPS-UVSQ, CESP, Renal and Cardiovascular Epidemiology team, Paris, France |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Institut National de la Santé Et de la Recherche Médicale, France |
| ClinicalTrials.gov Identifier: | NCT03381950 |
| Other Study ID Numbers: |
C12-30 |
| First Posted: | December 22, 2017 Key Record Dates |
| Last Update Posted: | October 11, 2019 |
| Last Verified: | October 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
chronic kidney disease prospective cohort study risk profile patient-reported-outcomes |
|
Kidney Diseases Renal Insufficiency, Chronic Renal Insufficiency Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |
Urogenital Diseases Male Urogenital Diseases Chronic Disease Disease Attributes Pathologic Processes |